The newly approved prefilled syringe for self-injection of Vyvgart Hytrulo will provide more convenience and flexibility for ...

The FDA has approved a subcutaneous self-injectable for adults with generalized myasthenia gravis who are anti-acetylcholine ...

As part of Patient Experience Week, Stewart Memorial Community Hospital is shining a spotlight on the remarkable care ...

for chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy after stabilization with intravenous immunoglobulin (IVIG) to prevent relapse of neuromuscular disability and ...

The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and ...

Roivant Sciences secures $5.2B for advancing late-stage drugs like IMVT-1402 & brepocitinib. Click here to read an analysis ...

Dianthus Therapeutics targets severe autoimmune diseases with DNTH103. Read more on DNTH's promise amid competitive ...

Shares of argenx SE ARGX rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART ...

antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART ® Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-second ...

HyQvia (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion) is a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP ...